A detailed history of Savant Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 22,118 shares of APLS stock, worth $663,540. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,118
Previous 13,598 62.66%
Holding current value
$663,540
Previous $521,000 22.26%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$28.84 - $41.15 $245,716 - $350,598
8,520 Added 62.66%
22,118 $637,000
Q2 2024

Aug 05, 2024

BUY
$38.07 - $59.71 $517,675 - $811,936
13,598 New
13,598 $521,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.3B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Savant Capital, LLC Portfolio

Follow Savant Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Savant Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Savant Capital, LLC with notifications on news.